181 related articles for article (PubMed ID: 32223996)
1. Variations in novel cellular therapy products manufacturing.
Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
[TBL] [Abstract][Full Text] [Related]
2. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation.
Trento C; Bernardo ME; Nagler A; Kuçi S; Bornhäuser M; Köhl U; Strunk D; Galleu A; Sanchez-Guijo F; Gaipa G; Introna M; Bukauskas A; Le Blanc K; Apperley J; Roelofs H; Van Campenhout A; Beguin Y; Kuball J; Lazzari L; Avanzini MA; Fibbe W; Chabannon C; Bonini C; Dazzi F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2365-2370. PubMed ID: 30031938
[TBL] [Abstract][Full Text] [Related]
3. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
Dinh A; Stroncek DF
Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
[TBL] [Abstract][Full Text] [Related]
4. Manufacturing mesenchymal stromal cells for clinical applications: A survey of Good Manufacturing Practices at U.S. academic centers.
Phinney DG; Galipeau J;
Cytotherapy; 2019 Jul; 21(7):782-792. PubMed ID: 31182333
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
Mukherjee S; Reddy O; Panch S; Stroncek D
Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
[TBL] [Abstract][Full Text] [Related]
6. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
7. Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance.
Golay J; Pedrini O; Capelli C; Gotti E; Borleri G; Magri M; Vailati F; Passera M; Farina C; Rambaldi A; Introna M
Cytotherapy; 2018 Feb; 20(2):262-270. PubMed ID: 29246649
[TBL] [Abstract][Full Text] [Related]
8. The need for uniform and coordinated practices involving centrally manufactured cell therapies.
Stroncek D; Dinh A; Rai H; Zhang N; Somerville R; Panch S
J Transl Med; 2022 Apr; 20(1):184. PubMed ID: 35468789
[TBL] [Abstract][Full Text] [Related]
9. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments.
Vives J; Oliver-Vila I; Pla A
Cytotherapy; 2015 Aug; 17(8):1009-14. PubMed ID: 25769789
[TBL] [Abstract][Full Text] [Related]
10. Cell therapy worldwide: an incipient revolution.
Rao M; Mason C; Solomon S
Regen Med; 2015; 10(2):181-91. PubMed ID: 25835482
[TBL] [Abstract][Full Text] [Related]
11. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
12. Intersecting Worlds of Transfusion and Transplantation Medicine: An International Symposium Organized by the Canadian Blood Services Centre for Innovation.
Hodgkinson KM; Kiernan J; Shih AW; Solh Z; Sheffield WP; Pineault N
Transfus Med Rev; 2017 Jul; 31(3):183-192. PubMed ID: 28385575
[TBL] [Abstract][Full Text] [Related]
13. Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.
Holbro A; Baldomero H; Lanza F; Chabannon C; Snowden JA; Buser A; Infanti L; Worel N; Sureda A; Badoglio M; Passweg J; Bonini C;
Cytotherapy; 2018 Mar; 20(3):453-460. PubMed ID: 29352666
[TBL] [Abstract][Full Text] [Related]
14. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications.
Wuchter P; Bieback K; Schrezenmeier H; Bornhäuser M; Müller LP; Bönig H; Wagner W; Meisel R; Pavel P; Tonn T; Lang P; Müller I; Renner M; Malcherek G; Saffrich R; Buss EC; Horn P; Rojewski M; Schmitt A; Ho AD; Sanzenbacher R; Schmitt M
Cytotherapy; 2015 Feb; 17(2):128-39. PubMed ID: 24856898
[TBL] [Abstract][Full Text] [Related]
15. Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor cells for cell therapy.
Gastens MH; Goltry K; Prohaska W; Tschöpe D; Stratmann B; Lammers D; Kirana S; Götting C; Kleesiek K
Cell Transplant; 2007; 16(7):685-96. PubMed ID: 18019358
[TBL] [Abstract][Full Text] [Related]
16. Addressing the Manufacturing Challenges of Cell-Based Therapies.
de Almeida Fuzeta M; de Matos Branco AD; Fernandes-Platzgummer A; da Silva CL; Cabral JMS
Adv Biochem Eng Biotechnol; 2020; 171():225-278. PubMed ID: 31844924
[TBL] [Abstract][Full Text] [Related]
17. Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics.
Cottle C; Porter AP; Lipat A; Turner-Lyles C; Nguyen J; Moll G; Chinnadurai R
Curr Stem Cell Rep; 2022; 8(2):72-92. PubMed ID: 35502223
[TBL] [Abstract][Full Text] [Related]
18. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
Reed W; Noga SJ; Gee AP; Rooney CM; Wagner JE; McCullough J; McKenna DH; Whiteside TL; Donnenberg AD; Baker AK; Lindblad RW; Wagner EL; Mondoro TH
Transfusion; 2009 Apr; 49(4):786-96. PubMed ID: 19170985
[TBL] [Abstract][Full Text] [Related]
19. Considerations on chemistry, manufacturing, and control of stem cell products for Investigational New Drug application in China.
Lu J; Wei W
Biologicals; 2020 Nov; 68():3-8. PubMed ID: 33097376
[TBL] [Abstract][Full Text] [Related]
20. Concluding commentary on current trends to enhance the clinical safety of pediatric transfusion, focusing on prevention of untoward complications of HSC transplantation & newer strategies for improving the standards of safety/quality of stem cells expansion for cellular therapy.
Sniecinski I; Seghatchian J
Transfus Apher Sci; 2018 Jun; 57(3):378-383. PubMed ID: 29778713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
